9 Meters Biopharma is a business based in the US. 9 Meters Biopharma shares (INNT) are listed on the NASDAQ and all prices are listed in US Dollars. 9 Meters Biopharma employs 8 staff and has a market cap (total outstanding shares value) of 0.00.
Our top picks for where to buy 9 Meters Biopharma stock
How to buy 9 Meters Biopharma stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – INNT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy 9 Meters Biopharma stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
9 Meters Biopharma stock price (NASDAQ: INNT)
Use our graph to track the performance of INNT stocks over time.9 Meters Biopharma shares at a glance
52-week range | $0.00 - $0.00 |
---|---|
50-day moving average | $0.73 |
200-day moving average | $0.61 |
Wall St. target price | $10.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.49 |
Is it a good time to buy 9 Meters Biopharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
9 Meters Biopharma financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -193.21% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | $0.14 |
Market Capitalization | $23.1 million |
TTM: trailing 12 months
9 Meters Biopharma share dividends
We're not expecting 9 Meters Biopharma to pay a dividend over the next 12 months.
Have 9 Meters Biopharma's shares ever split?
9 Meters Biopharma's shares were split on a 1:10 basis on 31 January 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your 9 Meters Biopharma shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for 9 Meters Biopharma shares which in turn could have impacted 9 Meters Biopharma's share price.
9 Meters Biopharma share price volatility
Over the last 12 months, 9 Meters Biopharma's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while 9 Meters Biopharma's is -0.5435. This would suggest that 9 Meters Biopharma's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, 9 Meters Biopharma has bucked the trend.
9 Meters Biopharma overview
9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long-acting GLP-2 analogue, both of which are under orphan indication selection. 9 Meters Biopharma, Inc. owns global rights to its products.
Frequently asked questions
nullWhat percentage of 9 Meters Biopharma is owned by insiders or institutions?
Currently 10.237% of 9 Meters Biopharma shares are held by insiders and 2.733% by institutions. How many people work for 9 Meters Biopharma?
Latest data suggests 8 work at 9 Meters Biopharma. When does the fiscal year end for 9 Meters Biopharma?
9 Meters Biopharma's fiscal year ends in December. Where is 9 Meters Biopharma based?
9 Meters Biopharma's address is: 8480 Honeycutt Road, Raleigh, NC, United States, 27615 What is 9 Meters Biopharma's ISIN number?
9 Meters Biopharma's international securities identification number is: US6544051096 What is 9 Meters Biopharma's CUSIP number?
9 Meters Biopharma's Committee on Uniform Securities Identification Procedures number is: 61174L501
More guides on Finder
-
Best paper trading platforms to practice trading with fake money [2024]
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
-
7 best day trading platforms of 2024
These are the best day trading platforms, according to Finder’s comprehensive analysis.
-
Trading for beginners: 11 best trading platforms to get started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 best international stock brokers to invest in foreign assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 best discount brokers of 2024 for low-cost trading and investing
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
10 best stock apps of 2024 to elevate your mobile trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
5 top graphene stocks to invest in today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question